In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
Agreement will expand clinical trials of glioblastoma drug
Doctors exhausted conventional treatments for Mike Schuster. Can an experimental OMRF drug stop his brain cancer? *** In the summer of 2010, Mike and Teresa Schuster took their two boys to Mexico’s Yucatan Peninsula. The Schusters live in Norman, where Teresa is an administrative assistant in the University of Oklahoma’s Office of Student Affairs and […]
How one OMRF scientist’s refusal to give up on a failed stroke drug has yielded new hope for treating brain cancer and hearing loss